Scientists have used vesicular stomatitis virus (VSV) as an experimental vaccine delivery system against infectious diseases, including Ebola, Marburg, and Lassa fever viruses—but could people inoculated with those vaccines become a threat to transmit VSV to livestock? Read more about the NIAID study of VSV Ebola virus vaccine that shows no transmission threat to livestock.
Scientists have added new molecular evidence that the Ebola virus (EBOV) circulating in West Africa since late 2013 is no more virulent than EBOV seen in previous outbreaks. Read more about the NIH Ebola study that shows consistent immune inhibition by historic and recent Ebola virus strains.
Researchers developed a vaccine based on the established rabies virus vaccine that, when tested in mice, proved safe and provided protection against both rabies and Ebola infection. Then they tested three different types of the novel rabies/Ebola vaccine in nonhuman primates to determine their protective effect. Read more about how the rabies vaccine protects nonhuman primates against the deadly Ebola virus.
Sequential Immunization With VSV-Based Lassa and Ebola Vaccines Does Not Diminish Protection in Monkeys, NIAID Study Finds
Researchers studying vesicular stomatitis virus (VSV) as a delivery system, or vector, for candidate vaccines against the hemorrhagic fever viruses Ebola, Marburg, and Lassa report full protection in study animals when using Lassa and Ebola vaccines in sequence. Read more about the NIAID study that found sequential immunization with VSV-based lassa and Ebola vaccines does not diminish protection in monkeys.